
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Metastasis Research Group, University Department of Surgery, University of Wales College of Medicine, Cardiff CF14 4XN, United Kingdom [W. G. J., D. G., T. A. M., G. D., C. P., G. W., Ja. L., R. E. M.], and Department of Neurology; Kennedy Krieger Institute and John Hopkins School of Medicine, Baltimore, Maryland 21205 [R. A., Jo. L.]
Purpose: Hepatocyte growth factor/scatter factor (HGF/SF) is known to increase the invasiveness and migration of cancer cells in vitro and induce angiogenesis. This study examined if inhibition of HGF/SF receptor expression by cancer cells and HGF/SF expression by stromal fibroblasts affects the growth of mammary cancer.
Experimental Design: Transgenes encoding ribozymes to specifically target human HGF/SF receptor (pLXSN-MET) or HGF/SF (pLXSN-HGF) were constructed using a pLXSN retroviral vector. Human mammary cancer cells MDA MB 231 was transduced with pLXSN-MET (MDA+/+). A human fibroblast cell line MRC5, which produces bioactive HGF/SF, was transduced with pLXSN-HGF (MRC5+/+). These cells were used in a nude mice breast tumor model.
Results: HGF receptor in MDA+/+ cells and HGF in MRC5+/+cells were successfully removed with respective ribozymes as shown by reverse transcription-PCR and Western blotting, respectively. MDA+/+ was found to have reduced invasiveness when stimulated with HGF/SF. MRC5+/+ exhibited a significant reduction in HGF/SF production. When injected into athymic nude mice, MDA+/+ exhibited a slower rate of growth, compared with the wild type (MDA-/-), and the cells transduced with control viral vector (MDA+/-). The growth of MDA-/- tumor was significantly enhanced when coimplanted with wild-type MRC5 (MRC5-/-), and the stimulatory effect was reduced when MRC5+/+ cells were coimplanted instead of MRC5-/-. The reduction of tumor growth was accompanied by reduction of angiogenesis, as demonstrated by the staining of VE-cadherin in primary tumor tissues.
Conclusions: Retroviral ribozyme transgenes targeting HGF/SF in fibroblasts or its receptor cMET in mammary cancer cells can reduce the growth of mammary cancer and associated angiogenesis by inhibiting paracrine stromaltumor cell interactions.
This article has been cited by other articles:
![]() |
M. Yanagisawa, D. Huveldt, P. Kreinest, C. M. Lohse, J. C. Cheville, A. S. Parker, J. A. Copland, and P. Z. Anastasiadis A p120 Catenin Isoform Switch Affects Rho Activity, Induces Tumor Cell Invasion, and Predicts Metastatic Disease J. Biol. Chem., June 27, 2008; 283(26): 18344 - 18354. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Francone, R. G. Landmann, C.-T. Chen, M. Y. Sun, E. J. Kuntz, Z. Zeng, R. P. Dematteo, P. B. Paty, and M. R. Weiser Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors Mol. Cancer Ther., April 1, 2007; 6(4): 1460 - 1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hiscox, N. J Jordan, W. Jiang, M. Harper, R. McClelland, C. Smith, and R. I Nicholson Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions Endocr. Relat. Cancer, December 1, 2006; 13(4): 1085 - 1099. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yanagisawa and P. Z. Anastasiadis p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness J. Cell Biol., September 25, 2006; 174(7): 1087 - 1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Jiang, G. Davies, T. A. Martin, C. Parr, G. Watkins, M. D. Mason, K. Mokbel, and R. E. Mansel Targeting Matrilysin and Its Impact on Tumor Growth In vivo: The Potential Implications in Breast Cancer Therapy Clin. Cancer Res., August 15, 2005; 11(16): 6012 - 6019. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G Jiang, G. Watkins, O. Fodstad, A. Douglas-Jones, K. Mokbel, and R. E Mansel Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 781 - 791. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |